Biotechnology Value Fund L P's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Apr 2, 2026
- Accession no.
- 0000921895-26-000895
- Filed
- Apr 2, 2026, 4:48 PM ET
- Trade date
- Mar 31, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $63.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | Director, 10% Owner |
| BVF Partners L PCIK 0001055947 | Director, 10% Owner |
| BVF IncCIK 0001056807 | Director, 10% Owner |
| Biotechnology Value Fund II LPCIK 0001102444 | Director, 10% Owner |
| Lampert Mark NCIK 0001233840 | Director, 10% Owner |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Director, Other: See Explanation of Responses |
| BVF Partners OS Ltd.CIK 0001660684 | Director, Other: See Explanation of Responses |
| BVF I GP LLCCIK 0001803805 | Director, 10% Owner |
| BVF II GP LLCCIK 0001803806 | Director, 10% Owner |
| BVF GP Holdings LLCCIK 0001803809 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Class A Ordinary Shares, $0.0001 par value | SSaleDisposed | −1,932,354 | $16.79 | −$32,444,223.66 | 8,302,735 | Direct | |
| Mar 31, 2026 | Class A Ordinary Shares, $0.0001 par value | SSaleDisposed | −1,569,116 | $16.79 | −$26,345,457.64 | 6,599,722 | Direct | |
| Mar 31, 2026 | Class A Ordinary Shares, $0.0001 par value | SSaleDisposed | −248,530 | $16.79 | −$4,172,818.7 | 1,039,238 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.